top of page
"Swipe Right" for Biosimilars

By Ferrin Williams, PharmD MBA, Chief Pharmacy Officer 

Biosimilars are heating up and projected to generate $180B in savings over the next few years—without compromising quality of care. In this article, our Chief Pharmacy Officer Ferrin Williams, PharmD MBA, digs in on this hot topic, offers key considerations for plan sponsors, shares Scripta’s Savings Strategies, and explains why you’ll want to “swipe right” on biosimilars.

Weight-loss drugs: the scale gets heavier for self-insured plans

By Dr. Paul Bradley, Chief Medical Officer 

Weight-loss drugs are exploding in popularity and usage—causing unexpected spikes in Rx benefit costs. In this article, our co-founder and Chief Medical Officer, Dr. Paul Bradley, a practicing internist, provides unique insights for self-insured employers and plans as they weigh the risks versus benefits of covering this expensive new class of medications.

Consumers in Pain Over High Rx Prices, Ready to Take Action & in Need of Better Tools

Scripta surveyed 372 respondents, ages 18-60+, to delve deeper into American attitudes and behaviors around prescription drug pricing in Q1 2021. All respondents have health insurance through their employer and take one or more prescription drugs on a regular monthly basis. Ninety-six percent are willing to make a prescription change to save money on Rx. 

Survey Images.png
Self-Insured Employers: Making the Tough Decisions on Pharmacy Benefits

As employees make 2020-2021 healthcare elections, pharmacy benefits decision-makers reveal the method behind their plans. Scripta Insights surveyed 77 HR professionals at self-insured companies in August 2020. Their companies have a range of eligible employees from less than 1,000 to 10,000 or more. Results show employers and members could be saving a lot more on Rx.

bottom of page